Genentech Announces 93 Layoffs in California Amid Restructuring Efforts

Layoffs Announced:
Genentech is laying off 93 employees at its South San Francisco production facility, effective October 8, as part of a strategic plan to close the site.

Roles Affected:
The layoffs will impact various roles, including senior scientists, software engineers, project managers, data analysts, and a vice president.

Cancer Immunology Closure:
The layoffs follow the closure of Genentech's cancer immunology research department, which will be merged with the molecular oncology research team to form a unified cancer research entity.

Previous Layoffs:
This is the second round of layoffs for Genentech in 2024, following the announcement in April that it would reduce its workforce by about 3% across multiple departments, affecting over 400 jobs.

Industry Context:
The biotech industry is experiencing significant changes, including pressure from investors, regulators, and shifting drug development and manufacturing strategies, leading to job cuts and portfolio adjustments across various companies.